Anti-obesity potential of Capparis spinosa flower bud extracts in 3T3-L1 adipocytes and in high fat diet induced obese rats

Q4 Pharmacology, Toxicology and Pharmaceutics
K. Athesh, P. Brindha
{"title":"Anti-obesity potential of Capparis spinosa flower bud extracts in 3T3-L1 adipocytes and in high fat diet induced obese rats","authors":"K. Athesh, P. Brindha","doi":"10.29090/psa.2022.05.22.127","DOIUrl":null,"url":null,"abstract":"Obesity is a raising pandemic and it needs alternative approaches to prevent or treat, as the existing approaches are not highly effective. In this context, the present study has been designed with the aim to investigate the antiobesity potential of aqueous flower buds extract of Capparis spinosa L. (AFBECS) in 3T3-L1 adipocytes and in high fat diet (HFD) induced obesity thereby giving scientific validation to its traditional use. The 3T3-L1 preadipocytes were cultured and differentiated in DMEM in the absence and presence of various concentrations of AFBECS (25, 50, 100, 250 and 500 µg/mL) and the influence of the extracts on 3T3-L1 adipocyte viability and lipid accumulation were determined. The results showed that AFBECS maintained the viability of the 3T3-L1 adipocytes and also reduced the lipid accumulation in 3T3-L1 cells, dose dependently. In-vitro pancreatic lipase inhibition assay of AFBECS had shown moderate level of inhibition when compared with Orlistat. For in-vivo studies, HFD induced obese rats were treated with 100, 200 and 300 mg/kg of extracts for a period of 60 days using orlistat as standard drug. Anti-obesity potential was assessed using food intake, body weight, organ weights, adipocyte area, lipid profiles and many other blood biochemical parameters. Data of in-vivo studies revealed, significant reduction in body weight, fat-pad and organ weights of AFBECS treated animals. Altered levels of glucose, insulin, leptin, lipid profiles and antioxidant status were also normalized upon AFBECS treatment. These findings suggested that AFBECS was found to have prominent anti-obesity potential and exhibited its therapeutic efficacy by inhibiting adipogenesis, promoting lipolysis and ameliorating oxidative stress.","PeriodicalId":19761,"journal":{"name":"Pharmaceutical Sciences Asia","volume":"9 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmaceutical Sciences Asia","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.29090/psa.2022.05.22.127","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
引用次数: 1

Abstract

Obesity is a raising pandemic and it needs alternative approaches to prevent or treat, as the existing approaches are not highly effective. In this context, the present study has been designed with the aim to investigate the antiobesity potential of aqueous flower buds extract of Capparis spinosa L. (AFBECS) in 3T3-L1 adipocytes and in high fat diet (HFD) induced obesity thereby giving scientific validation to its traditional use. The 3T3-L1 preadipocytes were cultured and differentiated in DMEM in the absence and presence of various concentrations of AFBECS (25, 50, 100, 250 and 500 µg/mL) and the influence of the extracts on 3T3-L1 adipocyte viability and lipid accumulation were determined. The results showed that AFBECS maintained the viability of the 3T3-L1 adipocytes and also reduced the lipid accumulation in 3T3-L1 cells, dose dependently. In-vitro pancreatic lipase inhibition assay of AFBECS had shown moderate level of inhibition when compared with Orlistat. For in-vivo studies, HFD induced obese rats were treated with 100, 200 and 300 mg/kg of extracts for a period of 60 days using orlistat as standard drug. Anti-obesity potential was assessed using food intake, body weight, organ weights, adipocyte area, lipid profiles and many other blood biochemical parameters. Data of in-vivo studies revealed, significant reduction in body weight, fat-pad and organ weights of AFBECS treated animals. Altered levels of glucose, insulin, leptin, lipid profiles and antioxidant status were also normalized upon AFBECS treatment. These findings suggested that AFBECS was found to have prominent anti-obesity potential and exhibited its therapeutic efficacy by inhibiting adipogenesis, promoting lipolysis and ameliorating oxidative stress.
荆芥花蕾提取物对3T3-L1脂肪细胞和高脂饮食诱导的肥胖大鼠的抗肥胖作用
肥胖是一种日益严重的流行病,需要其他方法来预防或治疗,因为现有的方法不是很有效。在此背景下,本研究旨在探讨Capparis spinosa L. (AFBECS)含水花蕾提取物(AFBECS)在3T3-L1脂肪细胞和高脂饮食(HFD)诱导的肥胖中的抗肥胖潜力,从而为其传统用途提供科学验证。在不同浓度AFBECS(25、50、100、250和500µg/mL)的情况下,分别在DMEM中培养和分化3T3-L1前脂肪细胞,并测定其提取物对3T3-L1脂肪细胞活力和脂质积累的影响。结果显示,AFBECS能维持3T3-L1脂肪细胞的活力,并能降低3T3-L1细胞的脂质积累,且呈剂量依赖性。与奥利司他相比,AFBECS体外胰脂肪酶抑制试验显示出中等水平的抑制。在体内研究中,以奥利司他为标准药物,分别给予HFD诱导的肥胖大鼠100、200和300 mg/kg提取物60天。通过食物摄入量、体重、器官重量、脂肪细胞面积、脂质分布和许多其他血液生化参数来评估抗肥胖潜力。体内研究数据显示,AFBECS治疗动物的体重、脂肪垫和器官重量显著降低。在AFBECS治疗后,血糖、胰岛素、瘦素、脂质谱和抗氧化状态的改变也趋于正常。这些结果表明,AFBECS具有显著的抗肥胖潜力,并通过抑制脂肪生成、促进脂肪分解和改善氧化应激发挥其治疗作用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Pharmaceutical Sciences Asia
Pharmaceutical Sciences Asia Pharmacology, Toxicology and Pharmaceutics-Pharmacology, Toxicology and Pharmaceutics (all)
CiteScore
0.90
自引率
0.00%
发文量
59
期刊介绍: The Pharmaceutical Sciences Asia (PSA) journal is a double-blinded peer-reviewed journal in English published quarterly, by the Faculty of Pharmacy, Mahidol University, Thailand. The PSA journal is formerly known as Mahidol University Journal of Pharmaceutical Sciences and committed to the timely publication of innovative articles and reviews. This journal is available in both printed and electronic formats. The PSA journal aims at establishing a publishing house that is open to all. It aims to disseminate knowledge; provide a learned reference in the field; and establish channels of communication between academic and research expert, policy makers and executives in industry and investment institutions. The journal publishes research articles, review articles, and scientific commentaries on all aspects of the pharmaceutical sciences and multidisciplinary field in health professions and medicine. More specifically, the journal publishes research on all areas of pharmaceutical sciences and related disciplines: Clinical Pharmacy Drug Synthesis and Discovery Targeted-Drug Delivery Pharmaceutics Biopharmaceutical Sciences Phytopharmaceutical Sciences Pharmacology and Toxicology Pharmaceutical Chemistry Nutraceuticals and Functional Foods Natural Products Social, Economic, and Administrative Pharmacy Clinical Drug Evaluation and Drug Policy Making Antimicrobials, Resistance and Infection Control Pharmacokinetics and Pharmacodynamics.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信